I'm not sure either, you'd think those deals are kept pretty quiet until publicly released.
Also, you'd think Stamler and Bradbury still have strong connections at Teva to get 434 in front of them. Very big asset for the company to have their experience/connections come January. Biogen, Lilly, Roche, etc all other options too hopefully. RCT data de-risks a lot for pharma acquisitions so you'd think serious discussions will really kick-off Jan. Again, all just my opinion.
Also the AAS poster from the weekend has just been posted on Alterity website. They've the Biomuse data to aged-matched healthy adults to compare brain volume decline / atrophy, plus also show again the distinct pattern for MSA vs PD/LBD, and also that the worse atrophy due to MSA (inferred through comparing to those aged-matched adults) gives greater rise in UMSARS. Great research for the MSA space. Adding some more important reasoning of how a drug could slow/halt MSA UMSARS progression by stemming that volume decline / brain atrophy in these key areas.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)